Newly identified enzyme treats deadly bacterial infections in mice

Jul 02, 2008

By the time antibiotics made their clinical debut 70 years ago, bacteria had long evolved strategies to shield themselves. For billions of years, bacteria hurled toxic molecules at each other in the struggle to prosper, and those that withstood the chemical onslaught marched on. Now, with an uptick in antibiotic-resistant bacteria reaching alarming proportions, Rockefeller University scientists have identified an enzyme produced in viruses (called bacteriophages) that could stop these one-celled powerhouses dead in their tracks.

In research published this month in The Journal of Infectious Diseases, scientists led by Vincent Fischetti, head of the Laboratory of Bacterial Pathogenesis and Immunology, reveal that the newly identified enzyme, Cpl-1, can successfully treat symptoms of bacterial meningitis in young mice infected with Streptococcus pneumoniae, a highly resistant and deadly strain of bacteria. At a time when antibiotics have continued to prove futile, these findings may provide a solution to one of the more serious public health problems to hit this century.

“We have reached another critical milestone,” says Fischetti, who previously showed that Cpl-1 prevents ear infections in mice. “To argue that these enzymes can be clinically effective, we had to prove that they not only kill antibiotic-resistant bacteria but also reverse their symptoms of disease. And that’s what we did.”

Working with colleagues from the Institute for Infectious Diseases in Bern, Switzerland, Fischetti found that young mice infected with S. pneumoniae and then treated 18 hours later, once symptoms began, survived the potentially deadly infection. Moreover, Cpl-1 destroyed all traces of the most resistant and virulent strains of S. pneumoniae. In a test tube, this eradication took seconds; in the animal, it took a mere four hours and without collateral damage, suggesting that in mice, Cpl-1 is both a selective and safe treatment for drug-resistant bacterial meningitis.

Unlike the guerrilla warfare tactics of antibiotics, which give bacteria time to assemble their resources and develop resistance, phage enzymes strike with blitzkrieg speed and surprise, preventing bacteria from organizing a coherent defense. Without an effective strategy to fight them, bacteria are faced with a war they may not be able to win.

“We have had nothing to control these invasive diseases,” says Fischetti. “This approach may finally give us something.”

Citation: The Journal of Infectious Diseases 197(11): 1519–1522 (June 1, 2008)

Source: Rockefeller University

Explore further: Automated models can identify acute back pain in EMRs

add to favorites email to friend print save as pdf

Related Stories

Sharpening a test for tracing food-borne illness to source

Jun 23, 2014

Research from the University of Melbourne, Australia, could make it easier for public health investigators to determine if a case of food poisoning is an isolated incident or part of a larger outbreak. The findings are published ...

Research team implants human innate immune cells in mice

Mar 18, 2014

(Phys.org) —Overcoming a major limitation to the study of the origins and progress of human disease, Yale researchers report that they have transplanted human innate immune cells into mouse models, which ...

Garlic counteracts virulent bacteria

Feb 18, 2014

Garlic contains a substance that is particularly effective in encounters with even the hardiest bacterial strains. A young researcher at the University of Copenhagen will soon be defending his Ph.D. thesis on the positive ...

Clever chemistry improves a new class of antibiotics

Jan 17, 2014

(Phys.org) —A new class of molecules called acyldepsipeptides—ADEPs—may provide a new way to attack bacteria that have developed resistance to antibiotics. Researchers at Brown and MIT have discovered ...

Recommended for you

Asthma drug may help those with chronic hives

13 hours ago

(HealthDay)—A drug already used to treat moderate-to-severe allergic asthma appears to offer relief to people with chronic hives who haven't been helped by standard medications, new research suggests.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

menkaur
not rated yet Jul 02, 2008
yeah... and then there will be enzyme resistance ... you've got to use the medications in a right way and to control it - meaning - no selling it in shops etc...